The drug is a generic version of Pfizer’s high blood pressure treatment Procardia XL (nifedipine). The generic nifedipine has been approved in 30 mg, 60 mg and 90 mg extended release tablets. TWi already started shipping the drug to its US distributor partner (Par Pharmaceutical Companies) at the end of January 2014 and plans to start marketing the product as soon as possible.

The drug is the first in the company’s pipeline to be approved in the US, according to TWi’s General Manager, Yeh Liru. China Chemical & Pharmaceutical, which sells drugs and medical equipment, is responsible for making the drug on a contract basis for TWi Pharmaceutical.

Procardia XL 30 mg, 60 mg and 90 mg, extended release tablets marketed by Pfizer and the generic equivalent drugs marketed by other companies, had annual sales in 2013 of approximately US$116 million in the US, according to IMS data.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.